Lilly, Merus to develop T-cell redirecting bispecific antibodies

By The Science Advisory Board staff writers

January 19, 2021 -- Eli Lilly research and development group Loxo Oncology and oncology firm Merus have signed a research collaboration and exclusive license agreement with the goal of developing up to three CD3-engaging T-cell redirecting bispecific antibody therapies.

Under the deal, Merus will lead discovery and early-stage research efforts, while Loxo Oncology will handle additional research, development, and commercialization activities. Merus will receive $40 million in cash upfront, as well as an additional $20 million in equity investment by Lilly in Merus common shares, according to the vendors.

What's more, Merus is also eligible to receive up to $540 million in potential development and commercialization milestones per product, for a total of up to approximately $1.6 billion for three products. In addition, it will receive tiered royalties on product sales of any therapy commercialized from this collaboration, the companies said.

Lilly to acquire Prevail Therapeutics for $1B
Eli Lilly will acquire Prevail Therapeutics for a total consideration of up to $26.50 per share in cash, or an aggregate of approximately $1.04 billion,...
Lilly to provide U.S. with 650K more COVID-19 antibody doses
The U.S. government has purchased an additional 650,000 doses of Eli Lilly's neutralizing antibody, bamlanivimab, for $812.5 million.
FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...
Lilly, Precision BioSciences collaborate on genome editing
Eli Lilly and Precision BioSciences have entered a research collaboration and exclusive licensing agreement to utilize Precision's proprietary Arcus genome...
Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter